Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsSTU:A7L 37 PB Ratio is 72.26 as of Jul. 21, 2026, which is 2606% above its 10-year median of 2.67. GuruFocus rates STU:A7L with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, Crism Therapeutics ranks worse than 59.24% on this metric.
The historical rank and industry rank for Crism Therapeutics's PB Ratio or its related term are showing as below:
STU:A7L'
s PB Ratio Range Over the Past 10 Years
Min: 1.44 Med: 2.67 Max: 6.39
Current: 3.52
During the past 13 years, Crism Therapeutics's highest PB Ratio was 6.39. The lowest was 1.44. And the median was 2.67.
STU:A7L's PB Ratio is ranked worse than 59.24% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs STU:A7L: 3.52
During the past 12 months, Crism Therapeutics's average Book Value Per Share Growth Rate was -40.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -78.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Crism Therapeutics was 2.60% per year. The lowest was -78.30% per year. And the median was -10.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Crism Therapeutics PB Ratio Related Terms
Crism Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crism Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Crism Therapeutics (STU:A7L) has a PB Ratio of 72.26 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Crism Therapeutics and its competitors. This is 2606% above median its historical median of 2.67. Over the past decade, Crism Therapeutics' PB Ratio has ranged from 1.44 to 6.39. According to the industry distribution chart, Crism Therapeutics ranks #728 out of 1229 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Crism Therapeutics' PB Ratio too high?
Crism Therapeutics' current PB Ratio of 72.26 is 2606% above median its 10-year median of 2.67. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 6.39. The Biotechnology industry median PB Ratio is 2.79. Crism Therapeutics' value of 72.26 is 2490% above this industry median. Based on the distribution chart, Crism Therapeutics ranks #728 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Crism Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #728 out of 1229 companies for PB Ratio. This places Crism Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.79. Crism Therapeutics' value of 72.26 is 2490% above this benchmark. Historically, Crism Therapeutics' own PB Ratio has ranged from 1.44 to 6.39 over the past decade. While the company's 10-year median is 2.67 vs. the industry median of 2.79, Crism Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crism Therapeutics's current PB Ratio of 72.26 is 2490% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current PB Ratio is 72.26, which is 2606% above median its own 10-year median of 2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (STU:A7L) has a current PB Ratio of 72.26. The current PB Ratio is 72.26, which is 2606% above median its 10-year median of 2.67 and 2490% above the Biotechnology industry median of 2.79. Crism Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Crism Therapeutics (STU:A7L), the current PB Ratio is 72.26 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
37GF Score
Get the complete analysis for STU:A7L
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:A7L has been successfully added to your 
